KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Equity Average (2016 - 2025)

Pfizer (PFE) has disclosed Equity Average for 17 consecutive years, with $89.9 billion as the latest value for Q4 2025.

  • Quarterly Equity Average fell 0.65% to $89.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $89.9 billion through Dec 2025, down 0.65% year-over-year, with the annual reading at $87.6 billion for FY2025, 3.19% down from the prior year.
  • Equity Average for Q4 2025 was $89.9 billion at Pfizer, down from $91.1 billion in the prior quarter.
  • The five-year high for Equity Average was $100.3 billion in Q3 2023, with the low at $53.0 billion in Q4 2021.
  • Average Equity Average over 5 years is $85.4 billion, with a median of $90.2 billion recorded in 2022.
  • The sharpest move saw Equity Average skyrocketed 70.12% in 2022, then fell 9.97% in 2024.
  • Over 5 years, Equity Average stood at $56.6 billion in 2021, then surged by 66.84% to $94.4 billion in 2022, then fell by 1.23% to $93.2 billion in 2023, then dropped by 2.92% to $90.5 billion in 2024, then decreased by 0.65% to $89.9 billion in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $89.9 billion, $91.1 billion, and $89.8 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.